Impact of Tissue Plasminogen Activator (tPA) Treatment for an Atypical Acute Respiratory Distress Syndrome (COVID-19)
Status:
Withdrawn
Trial end date:
2021-02-15
Target enrollment:
Participant gender:
Summary
At the beginning COVID-associated lung injury was considered as typical ARDS, hence
respiratory and nonrespiratory treatments were delivered according to general principles for
this kind of illness. There is hypothesis that in predisposed individuals, alveolar viral
damage is followed by an inflammatory reaction and by microvascular pulmonary thrombosis. The
investigators suggest that thrombolytic therapy may be beneficial when compared to standard
care in patients with SARS-CoV-2 and severe respiratory failure.
Phase:
Phase 3
Details
Lead Sponsor:
Negovsky Reanimatology Research Institute
Collaborators:
Demikhov Municipal Clinical Hospital 68 Sklifosovsky Institute of Emergency Care